Netherlands Cancer Institute — Clinical Trial Site

64 Registered trials

25 Currently recruiting

Organisation

Netherlands Cancer Institute

Location

Amsterdam, Netherlands

Identifier

ORG-100009158

Address

Plesmanlaan 121, 1066 CX, Netherlands

Departments

/
1300:Clinical Research Unit
3001: Oncologie
761: Oncology
800: Pulmonology
Antoni van Leeuwenhoek
Cancer Institute
Clinical Research Unit
Clinical Research Unit (CRU)
Department of medical oncology
Department of Pulmonary Diseases
Department of Pulmonology
Department of Surgical Oncology
Dept of Medical Oncology
Division of Medical Oncology, Division of Molecular Oncology & Immunology
Gastroenterology and Hepatology
Gastrointestinal Oncology
General Surgery
Gynaecologie
Internal Medicine
Longkankercentrum en thoraxoncologie
Lung
Lung Cancer and Thoracic Oncology
Medical Oncology
MOD, Thoracic-Oncology
Nederlands Kanker Instituut
Netherlands Cancer Institute
NKI-AVL (Nederlands Kanker Instituut-Anthonie van Leeuwenhoek)
Oncologie
Oncology
Pulmonary Diseases
Pulmonology
Research Facility
Surgery
Surgical oncology unit
The Netherlands Cancer Institute
Thoracic Oncology
Thorax Oncology

Clinical trials at this site (64)

Search interface

GROINSS-V III Recruiting

2023-508722-99-00 Vulvar cancer 4 2020-11-19
A clinical study of the safety and effectiveness of an investigational cell therapy given with and without an investigational RNA-based vacc… Recruiting

2024-514962-38-00 Solid Tumors 1 2020-08-25
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-00… Recruiting

2024-512606-25-00 Advanced Solid Tumors 7 2019-12-20
A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma meta… Recruiting

2023-509265-21-00 In-transit metastasis of malignant melanoma 4 2019-04-08
A modular multi-Basket trial to improve personalized medicine in cancer patients Recruiting

2024-514238-19-00 Subjects with advanced solid tumour 4 2018-03-28
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended

2023-508073-87-00 Advance solid tumors harboring the KRAS G12C mutation 7 2024-11-14
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Metastatic leiomyosarcoma 5 2023-12-12
A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL… Ended

2022-502977-41-00 Non-Small Cell Lung Cancer 5 2023-06-23
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) Ended

2024-514930-19-00 metastatic and/or unresectable gastrointestinal stromal 9 2022-10-07
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended

2023-508723-12-00 gastroenteropancreatic neuroendocrine tumors 5 2021-09-27
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended

2024-514461-19-00 Solid Tumors 9 2021-09-09
Induction chemotherapy for locally advanced rectal cancer. Ended

2023-509758-74-00 Locally advanced rectal cancer 4 2021-07-21
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap… Ended

2023-506311-18-00 Advanced or metastatic solid tumors with KRAS G12C muta 1 2021-06-29
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended

2024-512238-13-00 Metastatic or Locally Advanced EGFR mutated Non-Small C 4 2021-02-10
An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat… Ended

2023-503421-19-00 Urothelial cancer 5 2020-08-26
Phase 1/2 Study of CLN-081 in Patients with Lung Cancer Ended

2024-516532-97-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 9 2020-03-26
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended

2023-506782-56-00 RET-Mutant Medullary Thyroid Cancer 5 2020-03-10
Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended

2023-505376-30-00 BRAF V600 mutation–positive unresectable or metastatic 4 2018-10-30
A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-… Ended

2024-515755-37-00 Limited disease small-cell lung cancer 4 2018-07-31
Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended

2023-505034-10-00 Locally Advanced or Metastatic Solid Tumors that Harbor 4 2016-08-01
EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit… Ended

2024-513509-30-00 Progressive or recurrent germ cell tumor (measurable or 5 2016-01-11
A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors Ended

2024-514745-10-00 Melanoma (or) malignant melanoma Non-small cell lung ca 1 2025-06-23